{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maus MV"],"funding":["NIAID NIH HHS","NCI NIH HHS"],"pagination":["2625-35"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3999751"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["123(17)"],"pubmed_abstract":["T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field of CAR T cells directed to hematologic malignancies, but the encouraging respons"],"journal":["Blood"],"pubmed_title":["Antibody-modified T cells: CARs take the front seat for hematologic malignancies."],"pmcid":["PMC3999751"],"funding_grant_id":["5R01 CA165206","P30 CA016520","R01 CA120409","P30 AI045008","R01 CA165206","K08 CA166039"],"pubmed_authors":["June CH","Grupp SA","Porter DL","Maus MV"],"additional_accession":[]},"is_claimable":false,"name":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies.","description":"T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field of CAR T cells directed to hematologic malignancies, but the encouraging respons","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Apr","modification":"2026-05-04T20:55:11.653Z","creation":"2026-04-07T20:55:15.4Z"},"accession":"S-EPMC3999751","cross_references":{"pubmed":["24578504"],"doi":["10.1182/blood-2013-11-492231"]}}